Provided by Tiger Fintech (Singapore) Pte. Ltd.

KALA BIO

8.09
+1.0915.57%
Post-market: 8.240.1500+1.85%19:59 EDT
Volume:434.05K
Turnover:3.30M
Market Cap:52.20M
PE:-1.06
High:8.41
Open:7.00
Low:6.70
Close:7.00
Loading ...

Ladenburg Thalmann Initiates KALA BIO at Buy With $12 Price Target

MT Newswires Live
·
11 Jul

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

GlobeNewswire
·
09 Jul

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

GlobeNewswire
·
07 Jul

Romulus K. Brazzell, Officer, Reports Disposal of Common Shares of Kala Bio Inc

Reuters
·
27 Jun

Kala Bio Inc. Officer Romulus K. Brazzell Reports Disposal of Common Shares

Reuters
·
05 Jun

KALA BIO Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
23 May

Kala Pharmaceuticals price target lowered to $12 from $15 at H.C. Wainwright

TIPRANKS
·
23 May

Kala Bio Q1 EPS $(1.41) Beats $(2.03) Estimate

Benzinga
·
14 May

Kala Bio Inc. Reports Q1 2025 Financials: Decrease in G&A and R&D Expenses, Cash Resources Expected to Fund Operations into 2026

Reuters
·
14 May

BRIEF-Kala Bio Q1 EPS USD -1.41

Reuters
·
14 May

KALA BIO Inc expected to post a loss of $2.03 a share - Earnings Preview

Reuters
·
09 May

Kala Pharmaceuticals (KALA) Receives a Buy from Oppenheimer

TIPRANKS
·
14 Apr

KALA BIO Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Apr

KALA BIO Advances Eye Disease Therapies with New Funding

TIPRANKS
·
01 Apr

Kala Bio Q4 EPS $(1.74) Beats $(2.28) Estimate

Benzinga
·
31 Mar

BRIEF-Kala Bio Q4 EPS USD -1.74

Reuters
·
31 Mar

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire
·
31 Mar

KALA BIO Inc expected to post a loss of $2.28 a share - Earnings Preview

Reuters
·
25 Mar

KALA BIO to Present at TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
26 Feb

KALA BIO Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Feb